Author Archive: Sougato Das

Sougato Das

Sougato Das is the Director of Partnering Products & Services at BIO. He leads the 25-person team that made partnering possible at BIO 2014, and is responsible for the evolution of partnering at BIO. Previously he was the product manager of CI, clinical intelligence and regulatory products at Thomson Reuters. Prior to that he was a consultant at Parexel, Siemens Medical, IMS Health, Sanofi, Glaxosmithkline, Merck and J&J. He also served as a speaker, instructor and editor at the Drug Information Association. Sougato holds a Masters in Information Science and a Bachelors in Electrical Engineering from the Pennsylvania State University.

Latest Posts

BIO’s Next Generation Partnering System to Open April 2015

partnering-HP-300x312

You’ve found your lead investor. Now it’s time to get to the next stage, and the best place to do so is the 2015 BIO International Convention. You have a meeting with Pfizer at 9:00 a.m. followed by a meeting with AstraZeneca/MedImmune at 9:30 a.m. Then a 30 minute break. Then you have four meetings back to back with Sofinnova, Takeda Ventures, Gates Foundation and Merck. After a quick lunch it’s back to partnering: make Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

SPARKs Fly When Stanford Profs Talk BD with Industry Leads

TheHill

5:30 PM, October 8th, 2014. Li Ka Shing Learning & Knowledge Center, Stanford University. Stanford’s SPARK Seminar Series provides a forum where BD leads can meet with aspiring academics to foster better collaboration and tech transfer. That said, much of the forum’s discussion has applicability outside of academia as well. Today Kanad Das (no relation), Associate Director of Partnering and Alliance Management at SPARK, has assembled a dream team of industry business development frontrunners to Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

A Patient at BIO Investor Forum

BIF-2014

“Sir?” The security guard walks to the Partnering desk, slightly confused. “Sir, there’s a man with no badge. He says he’s not registered for the conference. But he says he needs to talk to you.” At BIO events, you can always expect the unexpected. I nod to the guard. “Let him in.” A man. 70s. Stooped; hunched; gnarled. Disheveled. Faded tattoos on his forearms. Yet, a twinkle in his eye and an unexpected motorcycle helmet Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

How to Pitch to Investors

BIO Investor Forum

To help biotechs wow the scores of venture investors attending the BIO Investor Forum conference (San Fran, Oct 7-8), BIO held a “How to Pitch to Investors” web panel featuring David Collier, M.D., Managing Director, CMEA Capital; CEO, Velocity Pharmaceutical Development, Joe Sum, Partner & Analyst, EcoR1 Capital, Adam Cutler, Managing Director, Trout Group, and Tony Tontat, Capital Access Advisors/Boston. The recording of this can’t-miss web panel is here: Here’s a recap of the first Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Corporate Venture Capital Company Profiles

cvc

To celebrate BIO Investor Forum, and, of course, Halloween, the Partnering Team over at BIO put together a succinct and definitive guide to the SCARY biopharma-related corporate venture capitalists (CVCs). Join us at BIO Investor Forum for the opportunity to have private 30-minute meetings with almost all the CVCs in our guide! Now, some SPOOKY facts about modern-day CVCs, based on publicly available information: CVCs prefer to be minority investors (generally contributing less than 20%). Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,